Brief: Scopus Biopharma Completes Recapitalization To Enhance Shareholder Value
18/10/2022 14:28
Oct 18 (Reuters) - Scopus Biopharma Inc SCPS.O :
* SCOPUS BIOPHARMA COMPLETES RECAPITALIZATION DESIGNED TO
ENHANCE
SHAREHOLDER VALUE
* SCOPUS BIOPHARMA INC - IMMUNO-ONCOLOGY SUBSIDIARY, DUET
BIOTHERAPEUTICS, INDEPENDENTLY VALUED AT $25 MILLION
* SCOPUS BIOPHARMA INC - DUET BEING POSITIONED TO GO PUBLIC
IN
2023
* SCOPUS BIOPHARMA INC - MAINTAINS APPROXIMATELY 90%
OWNERSHIP
STAKE IN DUET
Source text for Eikon: ID:nGNX94827c
Further company coverage: SCPS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Scopus Biopharma
See all newsBrief: Scopus Biopharma - Nasdaq Hearings Panel Informed Company, By Letter Dated December 15, Of Its Determination To Delist Co's Common Stock From Nasdaq
Brief: Scopus Biopharma Completes Recapitalization To Enhance Shareholder Value
Brief: Scopus Biopharma Says Received Additional Non-Compliance Letter From Nasdaq
Brief: Scopus Biopharma Received Deficiency Letter From Nasdaq
Brief: Scopus BioPharma Inc- On April 4, Received Deficiency Notification Letter From Nasdaq Indicating Co Was Not In Compliance With Nasdaq Listing Rule